Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Gerosynth is a specialty chemical company dedicated to providing high-purity research chemicals and compounds for the geroscience and longevity research communities. The company specializes in the synthesis and distribution of molecules that target biological pathways associated with aging, such as NAD+ metabolism, cellular senescence, and autophagy. Their product catalog includes well-characterized compounds like NMN, senolytics, and sirtuin activators, which are utilized by researchers to investigate interventions for age-related diseases. By ensuring the availability of high-quality, validated reagents, Gerosynth supports the acceleration of pre-clinical discovery and the development of potential anti-aging therapies. The company operates primarily as a supplier to academic institutions and biotechnology firms globally. Gerosynth's focus on the "Geroscience Hypothesis" positions it as a key resource for labs exploring the fundamental drivers of biological aging.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Gerosynth Labs.